Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?

Current Opinion in Oncology

Volumn 21, Issue 4, 2009, Pages 360-366

  Blay, Jean Yves ^a,b   Adenis, Antoine ^c   Ray Coquard, Isabelle ^a   Cassier, Philippe A ^b   Cesne, Axel Le ^d  

^a CENTRE LÉON BÉRARD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Adjuvant; Duration; Gastrointestinal stromal tumour; Imatinib; Resistance

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; SUNITINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER RESISTANCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HIGH RISK PATIENT; HUMAN; INTESTINE RESECTION; MAINTENANCE THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67650312580     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832c95f8     Document Type: Review

References (34)

1. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005; 103:821 -829.
2. Dematteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-58.
3. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-465.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70-83.
5. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580.
6. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813-3825.
7. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61:8118-8121.
8. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349.
9. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156:791 - 795.
10. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160:1567-1572.
11. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708-710.
12. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23:5357-5364.
13. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004; 84:874-883.
14. Taniguchi M, NishidaT, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59:4297-4300.
15. Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006; 37:1527-1535.
16. Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007; 31:113-120.
17. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20:3898-3905.
18. Blay JY, Bonvalot S, Casali PC, et al. GIST Consensus Meeting Panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16:566-578.
19. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 (Suppl 2):S1 -S29.
20. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480.
21. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421-1423.
22. Verweij J, Van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39:2006-2011.
23. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-1134.
24. Blanke CD, Rankin C, Demetri GD, et al. PhaseIII randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastaticgastrointestinal stromal tumors expressing the kitreceptortyrosine kinase: S0033. J Clin Oncol 2008; 26:626-632.
25. Van Glabbeke MM, Owzar K, Rankin C, et al.comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients (pts). J Clin Oncol 2007; 25 (18-Suppl):10004.
26. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer 2005; 41:1751 -1757.
27. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42:1093-1103.
28. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25:1107-1113.
29. Le Cesne A, Ray-Coquard I, Bui B, et al. Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: a prospective randomized phase III trial of the French Sarcoma Group. J Clin Oncol 2007; 25 (18-Suppl):10005.
30. Casali PG, Jost L, Reichardt P, et al. , ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2):ii35-ii38.
31. Dematteo RP, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol 2007; 25 (18-suppl):10079.
32. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial ofstandard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620-625.
33. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-1338.
34. van den Abbeele AD, Badawi RD, Manola J, et al. Effects of cessation of imatinib mesylate (IM) therapy in patients with IM-refractory gastrointestinal stromal tumors as visualized by FDG-PET scanning [abstract]. J Clin Oncol 2004; 22:3012.